Format

Send to

Choose Destination
Heart Rhythm. 2017 Sep;14(9):1375-1379. doi: 10.1016/j.hrthm.2017.05.017. Epub 2017 May 11.

A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry.

Author information

1
Southampton General Hospital-University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. Electronic address: prr@hrclinic.org.
2
Centre Hospitalier Régional Universitaire de Tours-Hôpital Trousseau, Tours, France.
3
King Salman Heart Center-King Fahad Medical City, Riyadh, Saudia Arabia.
4
Universitaire ziekenhuizen Leuven-Campus Gasthuisberg, Leuven, Belgium.
5
University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
6
Electrophysiology Unit, Arrhythmology Department, Maria Cecilia Hospital, Cotignola, Italy.
7
Department of Cardiology, Odense University Hospital, Odense, Denmark.
8
Arrhythmia Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
9
Baylor Scott and White Healthcare, Baylor University Dallas, Texas; Medtronic, Mounds View, Minnesota.
10
Centre Hospitalier Régional Universitaire de Lille, Lille, France.
11
Hospital Universitari Clínic de Barcelona, Barcelona, Spain.
12
Universitats Spital Zürich, Zürich, Switzerland.
13
Medtronic, Mounds View, Minnesota.
14
Medtronic Bakken Research Center, Maastricht, The Netherlands.
15
Division of Cardiology, Section of Electrophysiology, Emory University, Atlanta, Georgia.

Abstract

BACKGROUND:

First-in-man studies of leadless pacemakers have demonstrated high rates of implant success, and safety and efficacy objectives were achieved. Outside of the investigational setting, there are concerns, particularly over cardiac effusion and perforation, device dislodgement, infection, telemetry, and battery issues.

OBJECTIVE:

The acute performance of the Micra transcatheter pacemaker from a worldwide Post-Approval Registry is reported.

METHODS:

The registry is an ongoing prospective single-arm observational study designed to assess the safety and effectiveness of Micra in the post-approval setting. The safety end point was system- or procedure-related major complications at 30 days post implant. We compared the major complication rate with that of the 726 patients from the investigational study. Electrical performance was also characterized.

RESULTS:

The device was successfully implanted in 792 of 795 registry patients (99.6%) by 149 implanters at 96 centers in 20 countries. Through 30 days post implant, a total of 13 major complications occurred in 12 patients, for a major complication rate of 1.51% (95% confidence interval, 0.78%-2.62%). Major complications included cardiac effusion/perforation (1, 0.13%), device dislodgement (1, 0.13%), and sepsis (1, 0.13%). After adjusting for baseline differences, the rate of major complications in the registry trended lower than the investigational trial (odds ratio, 0.58, 95% confidence interval, 0.27-1.25; P = .16). Early pacing capture thresholds were low and stable.

CONCLUSION:

Performance of the Micra transcatheter pacemaker in a real-world setting demonstrates a high rate (99.6%) of implant success and low rate (1.51%) of major complications through 30 days post implant. In particular, the rates of pericardial effusion, device dislodgement, and infection were low, reinforcing the positive results seen in the investigational study.

KEYWORDS:

Acute performance; Leadless pacemaker; Real-world performance

PMID:
28502871
DOI:
10.1016/j.hrthm.2017.05.017
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center